Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: "The cost of the drug wasn't mentioned a big oversight. Other news stories pegged it at about $35,000 a year. Adequate job. The story explained: ""But experts stress that Benlysta is not a miracle drug: It only worked in 35 percent of North American patients tested and was not effective for patients with the deadliest form of the disease. Additionally, it did not show positive results in African Americans, who are disproportionately affected by lupus."" There was no discussion of harms. An NPR story, by comparison, pointed out that ""There are side effects, of course, and some of them are pretty serious. In clinical tests involving about 2,100 people, 11 taking Benlysta died compared with 4 getting placebo. About 6 percent of people taking Benlysta got serious infections compared with 5.2 percent on placebo."" The story offered an interesting historical perspective on the evidence: ""The company originally tested Benlysta, known generically as belimumab, as a treatment for rheumatoid arthritis. When a mid-stage trial in lupus patients failed to meet researchers' goals in 2006, many analysts wrote the drug off and downgraded the company's stock. But when scientists reanalyzed the data they found that the drug helped block the antibodies that cause lupus symptoms in a subset of patients."" No disease mongering of lupus. Two independent sources were quoted. Not applicable. With no other new drug approved for lupus in 56 years, there's not been much to compare it with. The story did state that some experts thought this ""could prompt development of other drugs that are even more effective in treating the debilitating immune system disorder."" The focus of the story is FDA approval of the new drug. The headline explains that the FDA approved the first new drug for lupus in 56 years. It's clear the story did not rely solely on a news release." Claim: FDA approves first new drug for lupus in 56 years

A: "Good caveats, including in the patient profiled, who said, ""It's a bittersweet thing for me because I have friends with lupus for whom this drug won't work. There's no one-size-fits-all for lupus and I'm just extremely fortunate that my lupus is mild and is helped by Benlysta."" The story should have discussed potential harms and costs. As the story explained, this was not only the first new lupus drug approved in 56 years, but it could be ""a milestone that medical experts say could prompt development of other drugs that are even more effective in treating the debilitating immune system disorder."""
****
Q: Paragraph: The company earned $728 million, or 67 cents per share, in the fourth quarter. That compared with $827 million, or 74 cents per share, in the year-earlier quarter, when Lilly took charges for asset impairments and restructuring. "Company sales were stronger than thought, but a lot of that upside came from drugs that are already off patent or about to lose patent protection," said Edward Jones analyst Judson Clark. Excluding special items, Lilly earned 74 cents per share, matching analysts' average forecasts, according to Thomson Reuters I/B/E/S. Shares in the company dropped 1.4 percent to 53.21, after earlier reaching their lowest in two weeks at $53.05. Lilly's global sales fell 2 percent to $5.81 billion, but topped Wall Street forecasts of $5.46 billion. Sales would have been flat if not for the stronger dollar, which lowers the value of sales in overseas markets. Sales of Cymbalta, which lost U.S. patent protection last month, fell 38 percent to $883 million. But they came in about $100 million higher than Wall Street expected, analysts said. Lilly's sales, earnings, and its share price, have been badly hurt since late 2011, when its Zyprexa schizophrenia drug lost U.S. patent protection. Once Lilly's biggest product, with annual sales of $5 billion, it now has sales of only $1.5 billion. The situation worsened last month, when Cymbalta - which also had $5 billion in annual sales at its peak - began facing cheaper generics in the United States. The company's "patent cliff" will become more daunting in March, when $1 billion-a-year osteoporosis drug Evista faces U.S. generics. "We haven't wasted the crisis," Chief Executive John Lechleiter said Thursday in a conference call with industry analysts. "We're more agile, we're leaner and I believe we're better operators today." Lilly has cut more than 5,000 employees from its workforce in order to reduce annual costs by $1 billion over the last three years to deal with patent expirations on its drugs. It has also restructured itself to focus on cancer and diabetes - lucrative specialties that are two of the company's longstanding strengths. Clark said sales of Cymbalta could eventually decline 80 percent, which has been the case for many other blockbuster medicines in recent years. He questioned whether gains for other products seen in the fourth quarter will be sustainable. Sales of many products over the quarter showed double-digit sales increases, including Lilly's Humalog insulin, Cialis anti-impotence treatment, Forteo and Evista osteoporosis drugs, and Straterra for attention deficit disorder. But price increases in the United States accounted for much of those sales gains. The Indianapolis drugmaker is expecting a return to company sales growth next year, from increased sales of drugs that still have patent protection and from launches of new treatments for cancer and diabetes. It hopes to launch three new drugs this year: ramucirumab for stomach cancer, and dulaglutide and empagliflozin for type 2 diabetes - the most common form of the disease, which is closely linked to obesity. Although analysts have forecast annual sales of more than $650 million for ramucirumab, they are concerned the new diabetes drugs may have a hard time competing with similar drugs already on the market. The company has introduced no new products in recent years. In a recent interview, Lechleiter said it was time for Lilly "to go back on offense", helped by a pipeline of nearly 40 medicines in mid- and late-stage studies, compared with only seven in those stages of development a decade ago. Claim: Lilly's quarterly sales largely offset Cymbalta slide.

A: Drugmaker Eli Lilly and Co's quarterly revenue fell far less than expected, it reported on Thursday, as plunging sales of its Cymbalta depression treatment were largely offset by higher revenues for most of its other prescription drugs.
****
Q: Paragraph: "Politicians and national media once again have turned their attention to Chicago's violence. The city's nearly 800 murders in 2016 prompted President Donald Trump to repeatedly liken parts of Chicago to sections of the Middle East. Trump also has said he will ""send in the feds"" to ""fix the horrible carnage,"" but no signs of federal intervention have been seen so far. Trump's focus on Chicago, combined with the recent murders of 2-year-old Lavontay White Jr., 11-year-old Takiya Holmes and 12-year-old Kanari Bowers, has only heightened interest in what is happening in Chicago. The subject came up as MSNBC's Willie Geist interviewed U.S. Sen. Dick Durbin, D-Ill., on Feb. 15. Geist asked Durbin why Chicago is so violent, especially in comparison to other major cities like New York, which saw a historically low murder rate in 2016. (The Chicago violence segment starts at 3:54) Durbin made the argument that Chicago, as a whole, doesn't suffer from constant violence. He said the gun violence only occurs in a few areas. ""You can almost pinpoint half of the gun violence deaths to two or three specific sections in the city,"" Durbin said. ""They are just areas of devastation, economically and otherwise."" Is Chicago's violence actually that concentrated? Murder across neighborhoods We reached out to Durbin's office to see where he found this data. His press secretary, John Normoyle, pointed to a Chicago Tribune article published on Feb. 1 titled, ""Violence in Chicago still stubbornly high; Trump reacts again."" The story cites Chicago Police Department Superintendent Eddie Johnson who, during a press conference, said half of Chicago's homicides in January occurred in three police districts: Englewood on the South Side and the West Side districts of Harrison and Austin. We followed up with the Police Department's News Affairs Office to verify that statement. The department's director of communication, Frank Giancamilli, sent back a press release from Feb. 1 that says the Englewood, Austin and Harrison police districts approximately made up half of Chicago's 51 murders in January. The distinction is important. Data from each police district crime map shows a total of 22of the 51 January murders can be attributed to the Englewood, Austin and Harrison districts. It's a significant chunk 43 percent but not exactly half. 'It's a tale of two cities' Loyola University criminology professor Arthur Lurigio said violence in these areas is hardly news. Violence has been rampant in the Englewood, Austin and Harrison areas since the 1960s, Lurigio said. ""Without even seeing the data, I would have picked those three districts,"" Lurigio said. ""These communities haven't changed, and I expect them to continue being this violent if they experience the same conditions."" This brings us to the second part of Durbin's statement: The areas in which gun violence is concentrated are plagued by other problems that feed the violence. ""Homicide doesn't occur in a vacuum,"" Lurigio said. ""Violence is a public health problem, but people only view it in a criminal aspect. People in these areas are plagued by other social, economic and health problems. Things like housing foreclosures, high unemployment and school closures. So a lot of young men devalue their own life because they don't see a future. There's no compunction about pulling the trigger."" There's data backing up Durbin and Lurigio's claims. According to U.S. Census data compiled by the Chicago Tribune, both Austin and Englewood have an unemployment rate of 21 percent compared to an 11.1 percent rate in Chicago overall. East Garfield Park and West Garfield Park both make up parts of the Harrison Police District and have unemployment rates of 15 and 25 percent, respectively. Likewise, those neighborhoods have considerably lower individual incomes and higher percentages of households in poverty than Chicago as a whole. ""Chicago is like a tale of two cities,"" Lurigio said ""It's a city that's been utterly neglected in some parts. Give the city money to repair infrastructure where its needs it most. Fix the primary school systems in these areas. Don't call murder a crime problem when the answers lie in investing in these blighted areas."" Our ruling In a recent interview with MSNBC, Durbin spoke about gun violence in Chicago. Durbin said of Chicago, ""You can almost pinpoint half of the gun violence deaths to two or three specific sections in the city. They are just areas of devastation economically and otherwise."" Durbin's office cited a news article that used statistics from the Chicago Police Department. A press release from CPD News Affairs Office confirms this. It read: ""Three districts (7, 11, 15) are responsible for approximately 50% of murders in January 2017."" We confirmed these statistics by looking at data available on crime maps posted on the CPD Harrison, Englewood and Austin district websites. Durbin's assessment of Chicago's homicides is accurate. He did say you can ""almost"" attribute half ofdeaths to a few communities and 43 percent are in certain west and south side neighborhoods. Acrime expert told us these trends have been consistent over the last five decades. Finally, we found data that shows there is a correlation between areas with high violence and economic hardship. Claim: You can almost pinpoint half of the gun violence deaths to two or three specific sections in the city. They are just areas of devastation, economically and otherwise.

A:
"In a recent interview with MSNBC, Durbin spoke about gun violence in Chicago. Durbin said of Chicago, ""You can almost pinpoint half of the gun violence deaths to two or three specific sections in the city. They are just areas of devastation economically and otherwise."" Durbin's office cited a news article that used statistics from the Chicago Police Department. A press release from CPD News Affairs Office confirms this. It read: ""Three districts (7, 11, 15) are responsible for approximately 50% of murders in January 2017."" We confirmed these statistics by looking at data available on crime maps posted on the CPD Harrison, Englewood and Austin district websites. Durbin's assessment of Chicago's homicides is accurate. He did say you can ""almost"" attribute half ofdeaths to a few communities and 43 percent are in certain west and south side neighborhoods. Acrime expert told us these trends have been consistent over the last five decades. Finally, we found data that shows there is a correlation between areas with high violence and economic hardship.
****